doxazosin and Bladder Neck Obstruction studies

Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.

Research Excerpts

Excerpt	Relevance	Reference
"The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)."	9.12	Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. ( Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006)
"To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH)."	9.08	Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. ( Kirby, RS, 1995)
"In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated."	9.07	29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. ( Bendix Holme, J; Christensen, MM; Elkjaer Husted, S; Jacobsen, F; Nielsen, J; Noer, I; Nørgaard, JP; Olesen, S; Rasmussen, PC; Wolf, H, 1994)
"Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors."	5.29	Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. ( Kirby, RS, 1994)
"The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)."	5.12	Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. ( Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006)
"To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH)."	5.08	Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. ( Kirby, RS, 1995)
"In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated."	5.07	29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. ( Bendix Holme, J; Christensen, MM; Elkjaer Husted, S; Jacobsen, F; Nielsen, J; Noer, I; Nørgaard, JP; Olesen, S; Rasmussen, PC; Wolf, H, 1994)
"To evaluate the efficacy and tolerability of doxazosin in the treatment of bladder outflow obstruction resulting from benign prostatic hyperplasia (BPH)."	5.07	A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. ( Abrams, P; Bryan, J; Carter, P; Chapple, CR; Christmas, TJ; Kirby, RS; Milroy, EJ, 1994)
"The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients."	5.07	Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. ( Bendix Holme, J; Christensen, MM; Husted, SE; Jacobsen, F; Nielsen, J; Noer, I; Nørgaard, JP; Olesen, S; Rasmussen, PC; Wolf, H, 1993)
"Patients with symptomatic bladder outlet obstruction and moderately enlarged prostates can receive durable relief from finasteride."	2.70	Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. ( Baldwin, KC; Ginsberg, PC; Harkaway, RC, 2001)
"The role of alpha-blockers for managing bladder outlet obstruction remains relatively unexplored in children."	2.69	alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. ( Austin, PF; Cain, MP; Casale, AJ; Homsy, YL; Masel, JL; Rink, RC, 1999)
"Doxazosin was safe and well tolerated."	1.38	Long-term safety, tolerability, and efficacy of α1-adrenergic blocker in young men with primary bladder neck obstruction: results from a single centre in China. ( Dong, C; Gao, W; Han, X; Jia, R; Li, B; Li, S; Xiao, C, 2012)
"Tamsulosin was also administered to male rats (group IV)."	1.33	The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. ( Bae, JH; Jung, PB; Lee, JG, 2005)
"Doxazosin and Y-27632 generate effective CCSM relaxation in the presence of BOO."	1.33	Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. ( Aslan, G; Demir, O; Esen, AA; Gidener, S; Murat, N, 2006)
" Dose-response curves for carbachol and isoproterenol showed a shift to the left in rat detrusor smooth muscles from partially obstructed bladder when compared with the results obtained in detrusor muscles from sham-operated bladder."	1.32	Doxazosin effects on cholinergic and adrenergic responses in rat isolated detrusor smooth muscle preparations from obstructed bladder. ( Kukul, E; Usta, C; Yalçinkaya, M, 2004)
"doxazosin was administered at bedtime for at least 3 months."	1.31	alpha1-Adrenergic blockers in young men with primary bladder neck obstruction. ( Chen, YT; Hsieh, CH; Wang, CC; Yang, SS, 2002)
"Doxazosin (dox) is a clinically effective alpha-adrenergic antagonist used in the treatment of symptomatic benign prostatic hyperplasia (BPH)."	1.31	Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. ( Das, AK; Eagen, G; Leggett, RE; Levin, RM; Whitbeck, C, 2002)
"Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors."	1.29	Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. ( Kirby, RS, 1994)

Research

Studies (31)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Change From Baseline in Urinary Growth Factor to Creatinine Ratio (GF/Cr)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	13 (41.94)	18.2507
2000's	15 (48.39)	29.6817
2010's	3 (9.68)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Gumrah, A	1
Tanidir, Y	1
Tinay, I	1
Ozyurek, M	1
Tarcan, T	1
Wang, M	1
Ren, XJ	1
Zhao, QH	1
Lin, LX	1
Wang, X	1
Zhao, Y	1
Ren, LM	1
Li, B	1
Gao, W	1
Dong, C	1
Han, X	1
Li, S	1
Jia, R	1
Xiao, C	1
Yang, SS	2
Wang, CC	2
Hsieh, CH	1
Chen, YT	2
Kyprianou, N	1
Usta, C	1
Kukul, E	1
Yalçinkaya, M	1
Lee, JY	1
Kim, HW	1
Lee, SJ	1
Koh, JS	1
Suh, HJ	1
Chancellor, MB	1
Donohoe, JM	1
Combs, AJ	1
Glassberg, KI	1
Athanasopoulos, AA	1
Perimenis, PS	1
Bae, JH	1
Jung, PB	1
Lee, JG	1
Athanasopoulos, A	1
Perimenis, P	1
Demir, O	1
Murat, N	1
Aslan, G	1
Gidener, S	1
Esen, AA	1
Rahardjo, D	1
Soebadi, DM	1
Sugandi, S	1
Birowo, P	1
Djati, W	1
Wahyudi, I	1
Bendix Holme, J	2
Christensen, MM	2
Rasmussen, PC	2
Jacobsen, F	2
Nielsen, J	2
Nørgaard, JP	2
Olesen, S	2
Noer, I	2
Wolf, H	2
Elkjaer Husted, S	1
Chapple, CR	1
Carter, P	1
Christmas, TJ	1
Kirby, RS	4
Bryan, J	1
Milroy, EJ	1
Abrams, P	2
Stockamp, K	1
Husted, SE	1
Feneley, MR	1
Dunsmuir, WD	1
Pearce, J	1
Gerber, GS	2
Kim, JH	2
Contreras, BA	2
Steinberg, GD	2
Rukstalis, DB	2
Ishizuka, O	2
Persson, K	1
Mattiasson, A	2
Naylor, A	1
Wyllie, M	1
Andersson, K	1
Steers, WD	1
Andersson, KE	1
Zagaja, GP	1
Austin, PF	1
Homsy, YL	1
Masel, JL	1
Cain, MP	1
Casale, AJ	1
Rink, RC	1
Caprino, L	1
Baldwin, KC	1
Ginsberg, PC	1
Harkaway, RC	1
Das, AK	1
Leggett, RE	1
Whitbeck, C	1
Eagen, G	1
Levin, RM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial[NCT01457573]	Phase 4	10 participants (Actual)	Interventional	2011-10-31	Completed
Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers[NCT01661621]	Phase 4	395 participants (Actual)	Interventional	2012-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The urinary growth factor (GF) to creatinine ratio may be potential biomarker for overactive bladder, based on published articles. Measuring the ratio at baseline and Month 3, comparing the difference after treatment with tamsulosin and solifenacin which may provide insight into how lower urinary tract symptoms in men progresses. (NCT01457573)
Timeframe: change from baseline score to Month 3

Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12

Intervention	ratio (Mean)
Baseline Characteristics	-19.61

Urine sample tested for urinary Nerve Growth Factor (uNGF as measured in pg/mL), a small secreted protein in the bladder that supports bladder function regulation, at baseline (pre-dose) and week 12/Month 3 post-dose, after using daily tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to week 12 (3 months)

Change in ICIQ LUTS QoL -International Consultation on Incontinence Modular Questionnaire LUTS Quality of Life for Male LUTS Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12

Intervention	pg/ml (Mean)
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	-10.9

Change in the International Consultation on Incontinence Modular Questionnaire on lower urinary tract symptoms quality of life survey for men, self administered, compared to Month 1, Month 2, and Month 3, after exposure to tamsulosin and solifenacin. The survey scoring is zero to 182, with 182 being the most bothersome and 0 to 1 being the least bothersome. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in ICIQ-MLUTS - International Consultation on Incontinence Modular Questionnaire for Male LUTS Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12

Intervention	units on a scale (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	34.60	38.30	-9.00

Measuring change in the International Consultation on Incontinence Modular Questionnaire for male lower urinary tract symptoms through a self administered survey at baseline compared to Month 1, Month 2, and Month 3, after exposure to tamsulosin and solifenacin. The survey score is a zero to 182 range with 182 being the most bothersome and zero to one being the least bothersome. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in IPSS-International Prostate Score Scale at Baseline Compared to Post Dose Survey at Month 1, 2, and Month 3/Week12.

Intervention	units on a scale (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	-22.40	-22.20	-29.8

The survey, IPSS-International Prostate Score Scale, survey responses measured 0-35, is collected at baseline compared to post dose survey response at Month 1, Month 2, and Month 3/Week12 post-dose. The lower the score is indicative of less or fewer urinary symptoms while 35 is consistent with more bothersome symptoms. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in Maximum Urinary Flow Rate (ml/s) at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12

Intervention	units on a scale (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	-2.00	-5.30	-7.33

Urination flow rate (measured in milliliters per second) at baseline (pre-dose), and Month 1, Month 2, and Month 3/Week 12 pose-dosing with tamsulosin and solifenacin. An average maximum urinary flow rate in males is 21 ml/sec aged 14-45 years-old and 12 ml/sec in males aged 46-65 years-old. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in PBC-Patient Perception of Bladder Condition at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12

Intervention	ml/s (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	-3.20	-3.90	-4.70

Change in the Perception of Bladder through a self administered survey at baseline compared to Month 1, Month 2, and Month 3, following exposure to tamsulosin and solifenacin. The survey score measures from zero to 6, with 6 being the most bothersome bladder symptoms and 0 to 1 being the least bothersome. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in Post Void Residual (mL) at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12

Intervention	units on a scale (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	1.29	0.29	0.00

Urine sample tested for urinary post void residual (measured in mL) at baseline (pre-dose), Month 1 and Month 2and week 12/Month 3 post-dose, post dose w/tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in PPUS-Patient Perception of Urinary Urgency Survey Score at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12

Intervention	ml (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	-6.90	-10.00	-3.60

The Patient Perception of Urinary Urgency self administered survey score has a maximum score 4, zero to four, for how severe a patient describes their urinary voiding frequency. Four is the most bothersome score, 0 or 1 is the least bothersome. Pre-dose / baseline score is compared at Month 1, Month 2, and Month 3, after dosing with tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3

Change in Urinary Growth Factor to Creatinine Ratio (GF/Cr) From Baseline Compared to Month 1/Week4 and Month 2/Week 8.

Intervention	units on a scale (Mean)
	Change at Month 1	Change at Month 2	Change at Month 3
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	0.00	0.30	0

Assessing the change from baseline to Month 1/Week 4 and Month 2/Week 8, of the urinary growth factor (GF) to creatinine ratio in men, which may be potential biomarker for overactive bladder, based on published articles. Measuring the ratio at baseline compared to Month 1 and Month 2 may provide insight into how lower urinary tract symptoms in men progresses. (NCT01457573)
Timeframe: change from baseline score to Mo.1/Wk4 and Mo.2/Wk8 scores

Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.1/Wk4 and Mo.2/Wk8

Intervention	ratio (Mean)
	Change at Month 1	Change at Month 2
Baseline Characteristics	-21.85	-20.56

Urine sample tested for urinary Nerve Growth Factor (uNGF as measured in pg/mL), a small secreted protein in the bladder that supports bladder function regulation, at baseline (pre-dose) compared to Month 1/Week 4 and Month 2/Week 8, post dosing with tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to Mo.1/Wk4 and Mo.2/Wk8

The Global Response Assessment (GRA) After the Treatment Day

Intervention	pg/ml (Mean)
	Change at Month 1	Change at Month 2
Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg	11.17	15.64

"Efficacy Using global response assessment (GRA) to compare the efficacy in Group 1 and Group 2 from baseline to 1month.~The global response assessment on a 6-point scale ranging from 1 No problems at all to 6 Many severe problems.~Changes of the global response assessment (GRA) improved or reduction by 1 points.~Change = Baseline minus Month 1 value~Safety:~Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness" (NCT01661621)
Timeframe: 1 month after initial treatment

The International Prostate Symptom Score (IPSS) Quality of Life (QoL) Score After the Treatment Day

Intervention	participants (Number)
	GRA≥1	GRA<1
Group 1	89	27
Group 2	218	61

"Efficacy:~Using the the the International Prostate Symptom Score (IPSS) quality of life (QoL) score to compare the efficacy in Group 1 and Group 2 from baseline to 1month.~The IPSS quality of life question score on a 7-point scale ranging from 0 Delighted to 6 Terrible.~IPSS-QoL ranges 0 to 6 (Delighted to Terrible)~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day

Intervention	units on a scale (Mean)
	Baseline	1 month
Group 1	3.91	2.82
Group 2	3.88	2.82

"Efficacy:~Using the total International Prostate Symptom Score (IPSS) to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS-voiding), 3 storage questions (IPSS-Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS-voiding + IPSS-Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

The IPSS Subscore (IPSS Storage) Questionnaires After the Treatment Day

Intervention	units on a scale (Mean)
	Baseline	1 month
Group 1	14.8	11.2
Group 2	18.0	10.8

"Efficacy:~Using the the IPSS subscore (IPSS Storage) to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

The IPSS Subscore (IPSS Voiding) Questionnaires After the Treatment Day

Intervention	units on a scale (Mean)
	Baseline	1 month
Group 1	9.51	6.40
Group 2	5.70	4.31

"Efficacy:~Using the the IPSS subscore (IPSS Voiding) questionnaires to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

The Maximum Flow Rate (Qmax) After the Treatment Day

Intervention	units on a scale (Mean)
	Baseline	1 month
Group 1	5.31	4.84
Group 2	12.3	6.49

"Efficacy:~Net change used the the maximum flow rate (Qmax) in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

The Postvoid Residual Volume (PVR) After the Treatment Day

Intervention	mL/s (Mean)
	Baseline	1 month
Group 1	13.1	13.6
Group 2	11.4	13.6

"Efficacy:~Net change used the the postvoid residual volume (PVR) in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

The Voided Volume After the Treatment Day

Intervention	mL (Mean)
	Baseline	1 month
Group 1	50.1	60.4
Group 2	53.9	42.9

"Efficacy:~Net change used the the voided volume in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month

Article	Year
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. The Journal of urology, 2003, Volume: 169, Issue:4 Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hype	2003
Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:14 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Benzila	2005
[Therapy of benign prostatic hyperplasia with alpha receptor blockers]. Der Urologe. Ausg. A, 1995, Volume: 34, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, A	1995
[Drugs for the treatment of benign prostatic hypertrophy]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2000, Volume: 52, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; D	2000

Article	Year
Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association, 2006, Volume: 13, Issue:11 Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Heart Rate; Humans; Male; Middle Aged	2006
29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scandinavian journal of urology and nephrology, 1994, Volume: 28, Issue:1 Topics: Aged; Double-Blind Method; Doxazosin; Drug Administration Schedule; Follow-Up Studies; Humans; Long-	1994
A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. British journal of urology, 1994, Volume: 74, Issue:1 Topics: Aged; Aged, 80 and over; Double-Blind Method; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperp	1994
Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology, 1995, Volume: 46, Issue:2 Topics: Aged; Blood Pressure; Double-Blind Method; Doxazosin; Humans; Hypertension; Male; Prostatic Hyperpla	1995
Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scandinavian journal of urology and nephrology, 1993, Volume: 27, Issue:1 Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Administration Schedule	1993
An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology, 1996, Volume: 47, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prostat	1996
Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months. Urology, 1997, Volume: 50, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Follow-Up Studies; Humans; Male; M	1997
Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. European urology, 1997, Volume: 32, Issue:1 Topics: Adrenergic alpha-Antagonists; Denmark; Double-Blind Method; Doxazosin; Humans; Hypertension; Male; N	1997
alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. The Journal of urology, 1999, Volume: 162, Issue:3 Pt 2 Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male;	1999
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urologia internationalis, 2001, Volume: 66, Issue:2 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyp	2001

Article	Year
The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction. Neurourology and urodynamics, 2017, Volume: 36, Issue:6 Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Carbachol; Disease Models, Animal; Doxazosin; Male	2017
Relaxant and contractile responses of detrusor muscle strips obtained from bladder outlet-obstructed rats treated with doxazosin enantiomers. Canadian journal of physiology and pharmacology, 2011, Volume: 89, Issue:12 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Agonists; Animals; Carbachol; Cholinergic A	2011
Long-term safety, tolerability, and efficacy of α1-adrenergic blocker in young men with primary bladder neck obstruction: results from a single centre in China. International urology and nephrology, 2012, Volume: 44, Issue:3 Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; China; Doxazosin; Humans; Lower Urinary	2012
alpha1-Adrenergic blockers in young men with primary bladder neck obstruction. The Journal of urology, 2002, Volume: 168, Issue:2 Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Dose-Response Relationship, Drug; Doxazosin; D	2002
Effectiveness of alpha1-adrenergic blockers in boys with low urinary flow rate and urinary incontinence. Journal of the Formosan Medical Association = Taiwan yi zhi, 2003, Volume: 102, Issue:8 Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Doxazosin; Humans; Male; Treatmen	2003
[Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow]. MMW Fortschritte der Medizin, 2003, Nov-20, Volume: 145, Issue:47 Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination;	2003
Doxazosin effects on cholinergic and adrenergic responses in rat isolated detrusor smooth muscle preparations from obstructed bladder. Journal of pharmacological sciences, 2004, Volume: 95, Issue:3 Topics: Adrenergic Agonists; Adrenergic alpha-Antagonists; Animals; Carbachol; Cholinergic Agonists; Dose-Re	2004
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU international, 2004, Volume: 94, Issue:6 Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P	2004
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU international, 2004, Volume: 94, Issue:6 Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P	2004
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU international, 2004, Volume: 94, Issue:6 Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P	2004
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU international, 2004, Volume: 94, Issue:6 Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P	2004
Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. The Journal of urology, 2005, Volume: 173, Issue:1 Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Child; Child, Preschool; Doxazosin; Electromyograph	2005
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU international, 2005, Volume: 95, Issue:7 Topics: Benzhydryl Compounds; Cresols; Doxazosin; Humans; Muscarinic Antagonists; Phenylpropanolamine; Tolte	2005
The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU international, 2005, Volume: 96, Issue:7 Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Doxazosin; Female; Male; Muscle Contraction;	2005
Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. The Journal of urology, 2006, Volume: 175, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Amides; Dose-Response Relationship, Drug; Doxazosin; Erectile Dy	2006
Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. British journal of clinical practice. Supplement, 1994, Volume: 74 Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Humans; Hypertension; Male;	1994
Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia. Urology, 1996, Volume: 47, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Double-B	1996
Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors. British journal of pharmacology, 1996, Volume: 117, Issue:5 Topics: Adrenergic alpha-Antagonists; Animals; Dihydroxyphenylalanine; Doxazosin; Female; Injections, Intra-	1996
Effects of spinal alpha 1-adrenoceptor antagonism on bladder activity induced by apomorphine in conscious rats with and without bladder outlet obstruction. Neurourology and urodynamics, 1997, Volume: 16, Issue:3 Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Dopamine Agonists; Doxazosin; Female; Hypertroph	1997
Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourology and urodynamics, 2002, Volume: 21, Issue:2 Topics: Adenosine Triphosphate; Administration, Oral; Adrenergic alpha-Antagonists; Animals; Blood Flow Velo	2002

doxazosin and Bladder Neck Obstruction